Phase 4 Study of Ranibizumab for the Treatment of Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Initial Fair Visual Acuity

Trial Profile

Phase 4 Study of Ranibizumab for the Treatment of Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Initial Fair Visual Acuity

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Branch retinal vein occlusion; Retinal oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Nov 2017 Planned End Date changed from 1 Jul 2016 to 1 Dec 2017.
    • 13 Nov 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2017.
    • 17 Nov 2015 Planned number of patients changed from 40 to 19 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top